RG
RPRX

Redmile Group’s Repros Therapeutics Inc. RPRX Stock Holding History

Redmile Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,500
Closed -$281K – 72
2013
Q3 		$281K Buy
+10,500
New +$225K 0.04% 47

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Redmile Group's RPRX Position: Q4 2013 in Review

Redmile Group sold out of Repros Therapeutics Inc. (RPRX) in Q4 2013, closing a stake of 10,500 shares — an estimated $281K sold.

Redmile Group first reported a position in RPRX in Q3 2013 and held it in 1 quarter. The position peaked at $281K in Q3 2013. 79 funds tracked by Wall St. Rank hold RPRX as of Q4 2013.

  • Redmile Group reported no remaining Repros Therapeutics Inc. position as of Q4 2013 after selling out during the quarter.
  • Redmile Group sold 10,500 Repros Therapeutics Inc. shares in Q4 2013, an estimated $281K.
  • Redmile Group first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 1 quarter.
  • Redmile Group's Repros Therapeutics Inc. position peaked at $281K in Q3 2013.
  • 79 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2013.

Based on Redmile Group's 13F filing for Q4 2013, filed 14 Feb 2014.